Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13449767 | 0.91 | KDM4E (0.41) | CA12CA1CA2CA4CA7 | |
| SCHEMBL6171927 | 0.83 | CA12 (0.52) | CA12CA1CA2CA4CA7 | |
| SCHEMBL26825677 | 0.83 | ALDH1A1 (0.52) | L3MBTL1TDP1CYP1A2ALDH1A1MAPT | |
| SCHEMBL2456174 | 0.82 | CA12 (0.50) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2350321 | 0.81 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL16744336 | 0.81 | PIM1 (0.36) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2354995 | 0.81 | PIM1 (0.36) | CA12CA1CA2CA4CA7 | |
| SCHEMBL11988218 | 0.79 | L3MBTL1 (0.55) | CA12CA1CA2CA4CA7 | |
| SCHEMBL6357684 | 0.79 | SMN1; SMN2 (0.47) | CA12CA1CA2CA4CA7 | |
| SCHEMBL8083251 | 0.78 | ALDH1A1 (0.48) | L3MBTL1TDP1LMNACYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| WO-2006052899-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISORDERS | NITROMED, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006030199-A1 | POLYMERISATION CATALYSTS | INEOS EUROPE LIMITED (GB) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006030192-A1 | POLYOLEFINS | INEOS EUROPE LIMITED (GB) | 2006-03-23 | — | — | WO | disclosed |
| EP-1606294-A1 | POLYMERISATION CATALYSTS | Innovene Europe Limited (GB) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004083221-A1 | POLYMERISATION CATALYSTS | INNOVENE EUROPE LIMITED (GB) | 2004-09-30 | — | — | WO | disclosed |
| EP-0647216-A4 | INHIBITION OF THE FORMATION OF NITROSAMINES. | — | 1995-05-17 | — | — | EP | disclosed |
| EP-0647216-A1 | INHIBITION OF THE FORMATION OF NITROSAMINES | SOLVAY INTEROX (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5324857-A | Adding free radical scavenger comprising phenol, aromatic polyol, thiol, or disulfide and chelating agent | SOLVAY INTEROX (US) | 1994-06-28 | — | — | US | disclosed |
| WO-1993022273-A1 | INHIBITION OF THE FORMATION OF NITROSAMINES | SOLVAY INTEROX (US) | 1993-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | CA12 2969/4885CA1 4385/4885CA2 4764/4885 |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | CA12 4608/4885CA1 4279/4885CA2 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.